Evidence map›Paper›PMID 40247049›Full record

ArticleScientific reports2025

Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms.

Colin H Quinn, Janet R Julson, Michael H Erwin, Hooper R Markert, Larua V Bownes, Jerry E Stewart, Sorina Shirley, Karina J Yoon, Jamie M Aye, James M Markert and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Colin H QuinnDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Janet R JulsonDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Michael H ErwinDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Hooper R MarkertDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Larua V BownesDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Jerry E StewartDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Sorina ShirleyDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA.
Karina J YoonDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jamie M AyeDivision of Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
James M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Elizabeth A BeierleDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7th Ave South, Lowder, Suite 300, Birmingham, AL, 35233, USA. elizabeth.beierle@childrensal.org.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8M
Surgical Oncology Research Training ProgramT32CA229102 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERBERT CHEN · 2018 to 2026
$3.2M
National Institute of Health 5T32GM008361NCI NIH HHS P30 CA013148NCI NIH HHS T32 CA229102NCI NIH HHS T32CA229102NIGMS NIH HHS T32 GM008361
6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present unique challenges due to their heterogeneity and limited treatment options. Oncolytic virotherapy has emerged as a promising therapeutic for other NETs and thus, we sought to investigate the potential of an engineered oncolytic herpes simplex virus (oHSV), M002, for GEP-NETS. We employed an established long-term passage GEP-NET cell line and a unique, human pediatric patient-derived xenograft GEP-NET line. We found the virus to effectively infect, replicate within, and kill both cell lines in vitro. Similar effects were noted in vivo, with M002 decreasing tumor growth and improving overall survival in mice bearing tumors from both the established cell line and human GEP-NET PDX. Overall, these studies provide an evaluation of an oncolytic HSV in GEP-NETs, highlighting its therapeutic potential and considerations for clinical translation.

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsOncolytic VirotherapyOncolytic VirusesPancreatic NeoplasmsSimplexvirusStomach NeoplasmsAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysNeuroendocrine tumorsOncolytic virusPatient derived xenograftsTranslational research

Identifiers

PMID40247049
PMCPMC12006505

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.